How GLP-1 Drugs Work—and Why They Do More Than Expected

A Gut Hormone With Outsized Power

GLP-1 receptor agonists — the drug class behind brand names like Ozempic, Wegovy, and Mounjaro — have become the most talked-about medications in a generation. Originally developed to treat type 2 diabetes, they have since transformed obesity medicine and are now being studied for a remarkably wide range of conditions, from heart disease to addiction.

At their core, these drugs mimic a natural hormone called glucagon-like peptide-1 (GLP-1), which the gut releases after eating. Understanding how they work explains why their effects reach far beyond the waistline.

How GLP-1 Drugs Work

When you eat, cells in the small intestine release GLP-1. This hormone does three things simultaneously: it stimulates insulin production to lower blood sugar, suppresses glucagon secretion to prevent the liver from dumping excess glucose, and slows gastric emptying so food stays in the stomach longer, promoting a feeling of fullness.

Natural GLP-1 breaks down within minutes. Synthetic versions like semaglutide are engineered to resist degradation, extending their half-life so a single weekly injection maintains steady effects. According to the Cleveland Clinic, the first GLP-1 agonist — exenatide — won FDA approval in 2005. Since then, chemists have refined the molecules for longer action, greater potency, and oral delivery.

Crucially, GLP-1 receptors are not only found in the pancreas and gut. They are also present in the brain's hypothalamus, where the hormone activates satiety neurons and suppresses hunger neurons, according to research published in Signal Transduction and Targeted Therapy. This dual action — slowing digestion and rewiring appetite signals in the brain — is what makes the drugs so effective for weight loss.

Weight Loss That Rivals Surgery

Clinical trials have documented striking results. In a phase III study, patients on semaglutide lost an average of 14.9% of their body weight over 68 weeks, compared with 2.4% for those on placebo. Oral semaglutide delivers roughly 13.7% weight loss over 64 weeks, approaching the results of its injectable counterpart, according to data reviewed by Harvard Health.

Benefits Beyond the Scale

What has surprised researchers most is the expanding list of conditions GLP-1 drugs appear to improve.

Heart and Kidneys

Multiple clinical trials show GLP-1 agonists reduce major adverse cardiovascular events — heart attacks, strokes, and cardiovascular death — in patients with type 2 diabetes, according to the MedStar Health research summary. A landmark semaglutide trial also found the drug slowed the progression of chronic kidney disease and lowered the risk of kidney failure, as reported by the National Kidney Foundation.

Addiction and Neurological Health

Perhaps the most unexpected finding comes from Washington University School of Medicine research: patients on GLP-1 medications showed reduced risk of substance addiction, with a 40% reduction in overdose and a 50% reduction in drug-related deaths over three years. Separate studies have linked the drugs to a decreased risk of Alzheimer's disease and dementia, suggesting GLP-1 receptors in the brain may have broad neuroprotective effects.

Side Effects and Caveats

GLP-1 drugs are not without drawbacks. The most common side effects are gastrointestinal — nausea, vomiting, and diarrhoea — particularly during the first weeks of treatment. More serious risks include pancreatitis, kidney stones, and potential thyroid concerns in animal studies, according to a large-scale analysis from Washington University.

There is also a rebound problem. Research shows that stopping GLP-1 medications can erase cardiovascular benefits within two years, with heart attack and stroke risk climbing by up to 22%. Weight regain after discontinuation is common, raising questions about whether these drugs require lifelong use.

What Comes Next

The next generation of drugs targets multiple hormone receptors simultaneously. Tirzepatide (Mounjaro, Zepbound) activates both GLP-1 and GIP receptors, while experimental triple agonists add glucagon receptor activation. Researchers are also developing oral formulations that could eliminate the need for injections entirely.

With a market projected to exceed $100 billion and clinical trials underway for liver disease, sleep apnoea, and heart failure, GLP-1 drugs have moved from a diabetes niche to the centre of modern medicine — reshaping how doctors think about obesity, metabolic disease, and the gut-brain connection.